# VENOUS THROMBOEMBOLISM (VTE)

## 定義

• Superficial thrombophlebitis: pain, tenderness, erythema along superficial vein

• Deep venous thrombosis (DVT): **_Proximal_** = thrombosis of iliac, femoral, or popliteal veins (nb, “superficial” femoral vein part of deep venous system). **_Distal_** = calf veins below knee; lower risk of PE/death than proximal (_Thromb Haem_ 2009;102:493).

• Pulmonary embolism (PE): thrombosis originating in venous system and embolizing to pulmonary arterial circulation; 1 case/1000 person y; 250,000/y (_Archives_ 2003;163:1711)

## Risk factors

• Virchow’s triad for thrombogenesis

**stasis:** bed rest, inactivity, CHF, CVA within 3 mo, air travel >6 h (_NEJM_ 2001:779)

**injury to endothelium:** trauma, surgery, prior DVT, inflam, central catheter

**thrombophilia:** genetic disorders (qv), HIT, OCP, HRT, tamoxifen, raloxifene

• Malignancy (12% of “idiopathic” DVT/PE; _Circ_ 2013;128:2614)

• History of thrombosis (greater risk of recurrent VTE than genetic thrombophilia)

• Obesity, smoking, acute infection, postpartum (_JAMA_ 1997;277:642; _Circ_ 2012;125:2092)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Thromboprophylaxis</b> (<span><i>Chest</i> 2012;141:e195S, 227S, 278S</span>)</p></td></tr><tr><td><p><b>Patient &amp; Situation</b></p></td><td><p><b>Prophylaxis</b></p></td></tr><tr><td><p>Low-risk med; same-day surg &amp; &lt;40 y</p></td><td><p>Early, aggressive ambulation</p></td></tr><tr><td><p>Minor surgery in mobile Pt</p></td><td><p>Mechanical Ppx</p></td></tr><tr><td><p>High-risk medical (immobile, h/o VTE, thrombophilia or cancer) &amp; most surgery 病人</p></td><td><p><b>UFH</b> 5000 U SC bid/tid, or <b>LMWH</b>, or fonda (if HIT ⊕), or mech Ppx (esp. if high bleed risk); ? extended Ppx with DOAC (<span><i>NEJM</i> 2016;375:534</span>). DOAC in ambul. cancer 病人 (<span><i>NEJM</i> 2019;380:711 &amp; 720</span>).<a id="st5"></a><a href="text/part0007_split_011.html#sst5">*</a></p></td></tr><tr><td><p>High-risk surg. (trauma, stroke, spinal cord injury, h/o VTE/thrombophilia)</p></td><td><p>[LMWH or UFH SC] + mech Ppx</p></td></tr><tr><td><p>Orthopedic surgery</p></td><td><p>LMWH [or fonda or warfarin (INR 2–3)] + mech Ppx; DOACs appear favorable vs LMWH</p><p>After 5 d of DOAC, ASA≈DOAC (<span><i>NEJM</i> 2018;378:699</span>)</p></td></tr></tbody></table>

For enox, 30 mg bid for highest risk or 40 mg qd for mod. risk or spinal/epidural anesth. [\*](text/part0007_split_011.html#st5)If Khorana score ≥2.

## 臨床表現—DVT

• Calf pain, swelling (>3 cm c/w unaffected side), venous distention, erythema, warmth, tenderness, palpable cord, ⊕ Homan’s sign (calf pain on dorsiflexion, seen in <5%)

• _Phlegmasia cerulea dolens:_ massive prox DVT with edema, _cyanosis_, pain, compart. synd.

• 50% of 病人 with sx DVT have asx PE

• Popliteal (Baker’s) cyst: may lead to DVT due to compression of popliteal vein

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>“Simplified Wells” Pretest Probability Scoring of DVT</b> (<span><i>JAMA</i> 2006;295:199</span>)</p></td></tr><tr><td colspan="3"><p>+1 point each for: active cancer (Rx ongoing or within 6 mo or palliative); paralysis, paresis, or recent immobilization of lower extremities; recently bedridden for ≥3 d or major surgery within 12 wk; localized tenderness along distribution of deep venous system; entire leg swelling; calf ≥3 cm larger than asx calf (at 10 cm below tibial tuberosity); pitting edema confined to sx leg; collateral superficial veins (nonvaricose); previous DVT</p><p>–2 points if alternative dx at least as likely as DVT</p></td></tr><tr><td colspan="3"><p><b>Pretest Probability Assessment</b> <span>(useful if outPt, less so if inPt; <i>JAMA IM</i> 2015;175:1112</span>)</p></td></tr><tr><td><p>Score ≤0</p></td><td><p>Score 1 or 2</p></td><td><p>Score ≥3</p></td></tr><tr><td><p>Low probability (5%)</p></td><td><p>Moderate probability (17%)</p></td><td><p>High probability (53%)</p></td></tr></tbody></table>

• For UE DVT, +1 point each for venous cath, local pain, & unilateral edema, –1 if alternative dx. ≤1 = unlikely; ≥2 = likely. U/S if likely or if unlikely but 異常 D-dimer (_Annals_ 2014;160:451)

## Diagnostic studies—DVT

• D-dimer: <500 helps 排除; ? use 1000 as threshold if low risk (_Annals_ 2013;158:93)

• Compression U/S >95% Se & Sp for sx DVT (lower if asx); survey whole leg if ≥ mod prob

### Figure 2-3 Approach to suspected DVT

![](https://i.imgur.com/A2z0fqp.jpg)

## 臨床表現—PE

• Dyspnea (~50%), pleuritic chest pain (~40%), cough (~23%), hemoptysis (~8%)

• ↑ RR (>70%), crackles (51%), ↑ HR (30%), fever, cyanosis, pleural friction rub, loud P2

• _Massive:_ syncope, HoTN, PEA; ↑ JVP, R-sided S3, Graham Steell (PR) murmur

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Simplified Wells Pretest Probability Scoring for PE</b> (<span><i>Annals</i> 2011;154:709)</span></p></td></tr><tr><td><p><span>•</span> Prior PE or DVT</p><p><span>•</span> Active cancer</p><p><span>•</span> Immobilization (bed rest ≥3 d) or surgery within 4 wk</p><p><span>•</span> Alternative dx less likely than PE</p></td><td><p><span>•</span> 臨床signs of DVT</p><p><span>•</span> HR &gt;100 bpm</p><p><span>•</span> Hemoptysis</p></td></tr><tr><td colspan="2"><p><b>Dichotomized Wells Probability Assessment</b></p></td></tr><tr><td><p>≤1 Variable = “Unlikely” (13% probability)</p></td><td><p>≥2 Variables = “Likely” (39% probability)</p></td></tr></tbody></table>

## Diagnostic studies—PE (_EHJ_ 2014;35:3033)

• CXR (limited Se & Sp): 12% 正常, atelectasis, effusion, ↑ hemidiaphragm, Hampton hump (wedge-shaped density abutting pleura); Westermark sign (avascularity distal to PE)

• ECG (limited Se & Sp): sinus tachycardia, AF; signs of RV strain → RAD, P pulmonale, RBBB, SIQIIITIII & TWI V1–V4 (McGinn-White pattern; _Chest_ 1997;111:537)

• ABG: hypoxemia, hypocapnia, respiratory alkalosis, ↑ A-a gradient (_Chest_ 1996;109:78) 18% with room air PaO2 85–105 mmHg, 6% with 正常 A-a gradient (_Chest_ 1991;100:598)

• D-dimer: high Se, poor Sp (~25%); ELISA has >99% NPV ∴ use to 排除 PE if “unlikely” pretest prob (_JAMA_ 2006;295:172); cut-off 500 if <50 y, 10× age if ≥ 50 y (_JAMA_ 2014;311:1117)

• Echocardiography: useful for risk stratification (RV dysfxn), but not dx (Se <50%)

• V/Q scan: high Se (~98%), low Sp (~10%). Sp improves to 97% for high-prob VQ. Use if pretest prob of PE high and CT not available or contraindicated. Can also exclude PE if low pretest prob, low-prob VQ, but 4% false (_JAMA_ 1990;263:2753).

• **CT angiography** (CTA; see Radiology inserts; _JAMA_ 2015;314:74): Se ~90% & Sp ~95%; PPV & NPV >95% if imaging concordant with 臨床suspicion, ≤80% if discordant (∴ need to consider both); ~1/4 of single & subseg may be false ⊕; CT may also provide other dx

• Lower extremity compression U/S shows DVT in ~9%, sparing CTA

### Figure 2-4 Approach to suspected PE

![](https://i.imgur.com/v9bktzX.jpg)

## Workup for idiopathic VTE (_NEJM_ 2015;373:697)

• **Thrombophilia workup:** ✔ if ⊕ FH, may be helpful but consider timing as thrombus, heparin and warfarin Δ results. Not helpful for Pt if will not Δ management (eg, plan for long-term anticoagulation regardless), although could be of use to relatives.

• **Malignancy workup:** 12% 病人 with “idiopathic” DVT/PE will have malignancy; age-appropriate screening adequate; avoid extensive workup

## Risk stratification for 病人 with PE

• **High risk (“massive”):** sustained hypotension (SBP <90), bradycardia, or cardiac arrest

• **Intermediate risk (“submassive”):** evidence of **right heart strain** without hypotension

echocardiogram: RV dysfxn (even if normal troponin) (_Chest_ 2013;144:1539)

biomarkers: ↑ troponin, ↑ BNP (_Chest_ 2015;147:685)

CTA: RV/LV dimension ratio >0.9 (_Circ_ 2004;110:3276)

臨床assessment (persistent tachycardia, low BP or hypoxemia) may prompt consideration of advanced Rx (see below)

• **Low risk:** no right heart strain or hypotension

## Whom to treat (_Lancet_ 2016;388;3060; _Chest_ 2016;149:315; _JAMA_ 2018;320:1583)

• **Superficial venous thrombosis:** elevate extremity, warm compresses, compression stockings, NSAIDs for sx. _Anticoag_ if high risk for DVT (eg, ≥5 cm, proximity to deep vein ≤5 cm, other risk factors) for 4 wk as ~10% have VTE within 3 mo (_Annals_ 2010;152:218)

• **LE DVT:** proximal → anticoag; distal → anticoag if severe sx, otherwise consider serial imaging over 2 wk and anticoag if extends (although if bleeding risk low, many would anticoag).

• **UE DVT:** anticoagulate (same guidelines as LE; _NEJM_ 2011;364:861). If catheter-associated, need not remove if catheter functional and ongoing need for catheter.

• **PE:** anticoagulate

## Anticoagulation options (_Chest_ 2016;149:315)

• _Initiate parenteral Rx immediately if high or intermed suspicion while dx testing underway_

• **Direct oral anticoag** (DOAC; _NEJM_ 2010;363:2499; 2012;366:1287; 2013;369:799 & 1406)

_preferred_ b/c as good/better than warfarin in preventing recurrent VTE with less bleeding

can give as sole anticoag with initial loading dose (riva or apixa) or initiate after ≥_5 d of parenteral anticoag_ (edox or dabi; 1st dose when d/c IV UFH or within 2 h before when next LMWH dose would have been due)

• **LMWH** (eg, enoxaparin 1 mg/kg SC bid _or_ dalteparin 200 IU/kg SC qd)

preferred over UFH (especially in _cancer_) except: renal failure (CrCl <25), extreme obesity, hemodynamic instability or bleed risk (_Cochrane_ 2004;CD001100)

can use as outPt bridge to long-term oral anticoagulation

• If cancer, LMWH ↓ recurrence and mortality c/w UFH & warfarin (_Lancet Oncol_ 2008;9:577); ✔ head CT for brain mets if melanoma, renal cell, thyroid, chorioCA; edoxaban may be as effective, but ↑ major bleeding, espec in GI malig (_NEJM_ 2018;378:615)

• **Fondaparinux:** 5–10 mg SC qd (_NEJM_ 2003;349:1695); use if HIT ⊕; avoid if renal failure

• **IV UFH:** 80 U/kg bolus → 18 U/kg/h → titrate to PTT 1.5–2.3 × cntl (eg, 60–85 sec); preferred option when contemplating thrombolysis or catheter-based Rx (qv)

• IV direct thrombin inhibitors (eg, argatroban, bivalirudin) used in HIT ⊕ 病人

• **Warfarin** (goal INR 2–3): start with parenteral anticoag unless instability and ? need for lytic, catheter-based Rx or surg; overlap ≥5 d with parenteral anticoag & until INR ≥2 × ≥24 h

## Systemic thrombolysis (_Chest_ 2012;141:e419S & 2016;149:315)

• Typically TPA 100 mg over 2 h or wt-adjusted TNK bolus; risk of ICH ~1.5%, ↑ with age

• Consider if low bleed risk with acute PE + HoTN or cardiopulm deterioration after anticoag

• **High-risk PE:** ↓ death & recurrent PE each by ~50% (_JAMA_ 2014;311:2414; _EHJ_ 2015;36:605) & lower PVR long term (_JACC_ 1990;15:65)

• **Intermediate-risk PE:** ↓ hemodyn decompensation, ↑ ICH & other major bleeding, ↓ mortality in short term, but no long-term benefit on mortality, PHT or RV fxn; ? consider if <75 y and/or low bleed risk (_NEJM_ 2014;370:1402; _JAMA_ 2014;311:2414; _JACC_ 2017;69:1536)

• _Half-dose lytic_ (50 mg or 0.5 mg/kg if <50 kg; 10-mg bolus → remainder over 2 h) in ~intermed. PE: ↓ pulm HTN & ? PE or death with ≈ bleeding vs. heparin alone (_AJC_ 2013;111:273)

• DVT: consider if (a) acute (<14 d) & extensive (eg, iliofemoral), (b) severe sx swelling or ischemia, and (c) low bleed risk

## Mechanical intervention

• **Catheter-directed** (fibrinolytic & thrombus fragmentation/aspiration; _Circ_ 2012;126:1917)

Consider if PE with hemodyn. compromise or high risk & not candidate for systemic lysis or surgical thrombectomy (_Circ_ 2011;124:2139). Preferred to systemic lytic by some centers.

U/S-assisted improves hemodynamics & RV fxn vs. anticoag alone (_EHJ_ 2015;36:597)

No benefit in extensive DVT (_NEJM_ 2017;377:2240)

• **Thrombectomy:** if large, proximal PE + hemodynamic compromise + contraindic. to lysis; consider in experienced ctr if large prox. PE + RV dysfxn (_J Thorac CV Surg_ 2005;129:1018)

• **IVC filter:** use if anticoag contraindic.; no benefit to adding to anticoag (_JAMA_ 2015;313:1627)

Complications: migration, acute DVT, ↑ risk of recurrent DVT & IVC obstruction (5–18%)

## Duration of full-intensity anticoagulation

• Superficial venous thrombosis: 4 wk

• 1st prox DVT _or_ PE 2° reversible/time-limited risk factor _or_ distal DVT: 3–6 mo

• 1st _unprovoked_ prox DVT/PE: ≥3 mo, then reassess; benefit to prolonged Rx Consider clot, bleed risk, Pt preference, and intensity of Rx when crafting strategy

• 2nd VTE event or cancer: indefinite (or until cancer cured) (_NEJM_ 2003;348:1425)

## Extended antithrombotic strategies

• After ≥6 mo of anticoag, following regimens compared with no extended Rx (or ASA):

• Full-dose DOAC: 80–90% ↓ recurrent VTE, 2–5× bleeding, but no signif excess in major bleeding (_NEJM_ 2010;363:2499; 2013;368:699 & 709)

• ½ dose apixa or riva: ≥75% ↓ recur. VTE, without ↑ bleeding (_NEJM_ 2013;368:699 & 2017;376:1211)

• Warfarin, either regular (_JAMA_ 2015;314:31) or low-intensity (_NEJM_ 2003;348:1425)

• Aspirin: 32% ↓ recurrent VTE (_NEJM_ 2012;366:1959 & 367:1979)

## Complications & prognosis

• Postthrombotic syndrome (23–60%): pain, edema, venous ulcers

• Recurrent VTE: 1%/y (after 1st VTE) to 5%/y (after recurrent VTE)

• Chronic thromboembolic PHT after acute PE ~2–3%, consider thromboendarterectomy

• Mortality: ~10% for DVT and ~10–15% for PE at 3–6 mo (_Circ_ 2008;117:1711)
